2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06E.06 Elucidating the Interplay Between Oncogenic Fusions and the Tumor Immune Microenvironment in Lung Adenocarcinoma

EP.06E.06 Elucidating the Interplay Between Oncogenic Fusions and the Tumor Immune Microenvironment in Lung Adenocarcinoma

Back to course

Pdf Summary

The study conducted by Chen Xuezhang and colleagues focuses on the relationship between oncogenic fusions and the tumor immune microenvironment in lung adenocarcinoma. The analysis involved tumor samples from patients with oncogenic fusions and those with non-targetable mutations, using a multiplex immunohistochemistry method to explore immune cell distributions in both tumor and stromal areas.<br /><br />In cases of non-small cell lung cancer, fusion mutations, which include ALK, RET, and NRG1 rearrangements, were linked to higher tumor malignancy and advanced cancer stages. Targeted therapy is often used for such cancers, although immunotherapy remains a consideration, especially for mutations like ROS1 and RET.<br /><br />Results showed a uniform immune landscape in patients with oncogenic fusions, with no notable differences between tumor and stromal areas, particularly among those with ALK rearrangements. Contrarily, in patients with non-targetable mutations, a reduced presence of immune cells like CD68/CD163- macrophages, PD-1 cells, and CD20 cells was observed in tumor areas compared to stromal areas. Interestingly, CD56 dim NK cells were more prevalent in tumors with oncogenic fusions, suggesting a distinct immune profile compared to non-targetable mutations. Additionally, an increased density of FoxP3 cells was noted in both tumor and stroma areas within the fusion group.<br /><br />The study concluded that the oncogenic fusion group exhibited a unique immune cell composition, highlighting differences in the presence of specific cell types such as NK and FoxP3 cells, distinguishing it from the immune environment of tumors with non-targetable mutations. This understanding could impact future therapeutic strategies for lung adenocarcinoma, emphasizing the importance of considering the tumor immune landscape in treatment decisions.

Asset Subtitle

Xuezhang Chen

Meta Tag

Speaker Xuezhang Chen

Topic Pathology and Biomarkers

Keywords

oncogenic fusions

tumor immune microenvironment

lung adenocarcinoma

multiplex immunohistochemistry

fusion mutations

ALK rearrangements

immune cell distribution

CD56 NK cells

FoxP3 cells

therapeutic strategies